Pimavanserin Aids Alzheimer’s Patients with Severe Psychosis, Acadia Reports

Pimavanserin Aids Alzheimer’s Patients with Severe Psychosis, Acadia Reports
Acadia Pharmaceuticals reports that pimavanserin was particularly effective in treating psychosis in Alzheimer’s disease patients who had severe psychotic symptoms, without triggering a deterioration in their cognition. The information, which stems from additional analyses of data gathered in a Phase 2 trial of pimavanserin in Alzheimer’s patients, was presented at the recent 10th Clinical Trials on

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *